Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify optimal molecular testing strategies for individual categories of MET dysregulation in patients with NSCLC along the continuum of care
- Assess safety and efficacy results from clinical trials investigating MET-targeted approaches for the management of patients with advanced NSCLC
- Determine the mechanistic rationale supporting the role of emerging therapies targeting c-MET overexpression
- Analyze ongoing trials as well as emerging data for novel strategies targeting c-MET overexpression in patients with NSCLC with or without EGFR mutations
Rebecca Heist, MD, MPH
Professor of Medicine
Harvard Medical School
Thoracic Oncology, MGH Cancer
Massachusetts General Hospital
Boston, MA
Disclosures: Consultant: Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck
Alex A. Adjei, MD, PhD, FACP
Chief, Cancer Institute
Director, Taussig Cancer Center
M. Frank Rudy and Margaret D. Rudy Distinguished Chair in
Translational Cancer Research
Cleveland Clinic
Cleveland, OH
Alex A. Adjei, MD, PhD, FACP has no relevant financial relationships with ineligible companies.
Sandip Patel, MD, FASCO
Professor, Medical Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics Program
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
University of California San Diego
San Diego, CA
Disclosures: Institutional Research Funding: A2 Bio, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech; Scientific Advisory Board: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Genentech, Illumina, Jazz, Merck, Pfizer
Jeremy Segal, MD, PhD
Vice Chair, Genomic Pathology
Professor of Pathology
University of Chicago
Chicago, IL
Disclosures: Advisor: AstraZeneca, Bristol Myers Squibb, OrisDx; Equity Recipient: OrisDx; Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Roche Diagnostics; Speaker: Roche Diagnostics
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here